FDA clears GE's updated cardiac CT

| | Health Imaging | Diagnostic Imaging
GE Healthcare has received FDA 510(k) clearance of its new cardiac imaging platform, the Discovery CT750 HD FREEdom Edition.

Based on FREEdom technologies (Fast Registered Energies & ECG), the Discovery CT750 HD FREEdom Edition is a three-prong technology, including: Motion FREEdom, with motion correction via SnapShot Freeze; Calcium FREEdom, with coronary visualization using Gemstone Spectral Imaging (GSI) Cardiac; and Horizon FREE opportunities, which provides plaque material composition assessment and perfusion calculations, the company said in its press release. 

GE said that the Discovery CT750 HD FREEdom Edition also merges GE’s SnapShot Pulse technology with GSI’s kV switching, allowing for a registered spectral CT dataset. And Calcium FREEdom means that coronary images with calcium suppression are possible for patients with high calcium burden.

The HD FREEdom Edition’s first U.S. installation was at the University of Washington (UW) in Seattle. HD FREEdom’s installation at UW follows around two dozen installations in Europe and Japan where physicians currently use SnapShot Freeze and GSI Cardiac in practice for coronary evaluation, and in plaque composition and myocardial perfusion assessment.





Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.